Oncotelic Therapeutics completed the integration of 28 million scientific abstracts into its proprietary PDAOAI platform, enabling the company’s AI‑enabled robotics system to operate with real‑time scientific knowledge embedded in automated workflows.
The integration is part of a partnership with TechForce Robotics, with initial commercial deployments expected in the coming weeks. This collaboration positions Oncotelic to bring its AI‑driven platform into regulated pharmaceutical development and manufacturing environments, potentially creating a new revenue stream and strengthening its competitive position in oncology and rare disease therapeutics.
The PDAOAI platform is an evidence‑interrogation system that indexes scientific literature, allowing researchers to interrogate evidence for testable hypotheses rather than relying on black‑box predictions. By embedding the totality of scientific knowledge into robotics, Oncotelic aims to transform drug development and production processes, improving compliance, reducing operational risk, and enhancing efficiency across the industry.
Management emphasized the strategic significance of the milestone. “We are moving from data to real‑world application,” said Dr. Vuong Trieu, Chairman and Chief Executive Officer. “By embedding the totality of scientific knowledge into robotics, we can look to transform how drugs are developed and produced, not just for us, but for the broader industry.” He added that the commercialization represents a significant step forward in bridging PDAOAI and automation within regulated pharmaceutical environments, and that the joint venture strategy has demonstrated the ability to unlock value through strategic partnerships.
Oncotelic also benefits from a 45% stake in GMP Bio, a joint venture that contributed a $249 million balance‑sheet increase in the most recent fiscal year. The partnership with GMP Bio and the new robotics platform signal a broader diversification strategy that expands the company’s footprint beyond its core biotech pipeline into scalable AI‑driven automation solutions.
The company’s move into AI‑enabled industrial automation reflects a broader industry shift toward intelligent, compliant automation solutions in pharmaceutical manufacturing. While the company has faced a challenging market environment, the new platform and partnership with TechForce Robotics position Oncotelic to capture emerging opportunities and strengthen its long‑term competitive advantage.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.